Transdermal sumatriptan closer to marketing
This article was originally published in Scrip
The private US company NuPathe plans to submit a US NDA next year for its novel iontophoretic sumatriptan patch, Zelrix. NuPathe expects Zelrix to be the first transdermal patch to be marketed for migraine.
You may also be interested in...
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.